Mrs Abigail Gonzalez, CSWI | |
7651 S Main St, Midvale, UT 84047-7101 | |
(801) 417-0131 | |
(801) 955-9411 |
Full Name | Mrs Abigail Gonzalez |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 7651 S Main St, Midvale, Utah |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396180386 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
1041C0700X | Social Worker - Clinical | 9307645-3501 (Utah) | Primary |
Entity Name | Utah Partners For Health |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1508299892 PECOS PAC ID: 8224262480 Enrollment ID: O20131002000251 |
News Archive
The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Evaluate Ltd. today announced the launch of a strategic sales analytics solution that provides commercial teams and the investment community with a comprehensive view of life sciences product sales by country.
Mylan Inc. and Pfizer Inc. today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis that will resolve pending patent litigation related to Intelliject's 505(b)(2) new drug application (NDA) for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis.
Is the current American drug overdose epidemic an isolated phenomenon? Have other high-income countries experienced similar increases in drug overdose mortality, or are they likely to going forward? A new study published in Population and Development Review addresses these questions.
Products that are "biosimilar" or interchangeable with a licensed biological product hold considerable promise for the treatment of a variety of medical conditions such as rheumatic diseases, and possibly at a reduced cost.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Mrs Abigail Gonzalez, CSWI 7651 S Main St, Midvale, UT 84047-7101 Ph: (801) 417-0131 | Mrs Abigail Gonzalez, CSWI 7651 S Main St, Midvale, UT 84047-7101 Ph: (801) 417-0131 |
News Archive
The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Evaluate Ltd. today announced the launch of a strategic sales analytics solution that provides commercial teams and the investment community with a comprehensive view of life sciences product sales by country.
Mylan Inc. and Pfizer Inc. today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis that will resolve pending patent litigation related to Intelliject's 505(b)(2) new drug application (NDA) for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis.
Is the current American drug overdose epidemic an isolated phenomenon? Have other high-income countries experienced similar increases in drug overdose mortality, or are they likely to going forward? A new study published in Population and Development Review addresses these questions.
Products that are "biosimilar" or interchangeable with a licensed biological product hold considerable promise for the treatment of a variety of medical conditions such as rheumatic diseases, and possibly at a reduced cost.
› Verified 5 days ago